Company Overview and News
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549
Leaked documents showed what could be Microsoft’s (MSFT - Free Report) hardware plans to 2020, new technology competing with Amazon Go and Office enhancements constituted the top Microsoft stories from last week. Here are the details-
AAPL MSFT SNE
Nintendo (OTCMKTS:NTDOY) and Microsoft (NASDAQ:MSFT) have seen their game console fortunes taking opposite trajectories. Nintendo stock has exploded out of the Wii U gutter on massive Switch sales, while the Xbox One has been somewhat of a disappointment.
A few years ago, virtual reality was being pushed as the next big thing in gaming, and Microsoft Corporation (NASDAQ:MSFT) was talking up Project Scorpio touting VR as a big part of its Xbox plans. Now, the company is backing off. In the aftermath of this year’s E3 gaming conference, MSFT says Xbox VR support is on hold. The news hasn’t moved Microsoft stock yet, but it could.
FB MSFT SNE SNEJF
These days, technological advancements isn’t merely about creating faster and more efficient machines. Instead, tech firms heavily emphasize connectivity, which represents the core basis of the “internet of things.” Considering the trend toward IoT, you’ll want to consider internet of things stocks sooner rather than later.
CYBR CY AMZN GRMN SNE NYTAB BBY SNEJF
After a three and a half year slide that saw its stock fall from $47 to under $13, GameStop Corp. (NYSE:GME) has been on an upswing for the past week. And yesterday, GME stock had a pop of over 3.6% on rumors were circulating that the company was exploring a sale. Yesterday evening, GameStop issued a press release confirming that it is in “exploratory discussion with third parties.”
T MSFT SNE GME
It has been barely over a month since its initial public offering, and already, HUYA (NYSE:HUYA) is making a huge impact. The IPO scene is a rough one to call, with popular names like Blue Apron (NYSE:APRN) and Snap (NYSE:SNAP) producing disappointing performances. Can upstart HUYA stock break this trend?
APRN JD HUYA SNE BIDU SNAP
Barely six months after inaugurating a tiny software-coding boot camp in a basement in Tokyo, Silicon Valley transplant Kani Munidasa stood before some of Japan’s top business leaders in February with a warning: software was threatening their future.
NTDTY 9613 SNE SNEJF
TOKYO (Reuters) - Barely six months after inaugurating a tiny software-coding boot camp in a basement in Tokyo, Silicon Valley transplant Kani Munidasa stood before some of Japan’s top business leaders in February with a warning: software was threatening their future.
NTDTY 9613 SNE SNEJF
TOKYO: Barely six months after inaugurating a tiny software-coding boot camp in a basement in Tokyo, Silicon Valley transplant Kani Munidasa stood before some of Japan's top business leaders in February with a warning: software was threatening their future.
NTDTY 9613 SNE SNEJF
IRAN NOTICE Re: Notice of Disclosure filed in Annual Report on Form 20-F under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934 Ladies and Gentlemen: Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of
REUTERS: Video game and electronics retailer GameStop Corp is holding talks with private equity firms about a potential transaction after receiving buyout interest, people familiar with the matter said on Monday.
EA SNE MSFT SNEJF GME
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
Silicon Investor Message Boards
This table lists all message boards related to SNE / Sony Corp. on message board site Silicon Investor.
as of ET